authors
-
Anna Kołodziej 2, Danuta Du¶ 1, Janusz Dembowski 2, Romuald Zdrojowy 2, Tomasz Szydełko 2, Jerzy Lorenz 2
- 1 Zakład Immunologii Nowotworów Instytut Immunologii i Terapii Do¶wiadczalnej PAN we Wrocławiu
Kierownik Instytutu: prof. dr hab. C. Radzikowski
2 Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik Kliniki: prof. dr hab. J. Lorenz
keywords
-
bladder carcinoma p53 expression
summary
- The aim of the study. p53 tumor suppressor gene is considered to play a
- significant role in carcinogenesis. Mutations in the p53 are the most fre±uent
- genetic abnormalities encountered in human malignancies. Our aim was to
- investigate the expression of p53 oncoprotein in superficial and invasive
- transitional cell bladder cancer (TCC) as well as its correlation with established
- Prognostic factors, such as histologic grade, tumor stage, DNA content and
- survival.
- Results. p53 tumor suppressor protein was overexpressed in 46.3% of TCC
- of 32 cases and more fre±uently in invasive than superficial TCCs and
- undetectable in the tumor adjacent to normal tissue. p53 positivity was related
- to the degree of differentiation and with the stage of the disease. p53
- overexprssion demonstrated a correlation with DNA ploidy. There was no
- correlation of recurrence related to p53 positive superficial tumors. There was
- a correlations with progression. When we combined ploidy and p53 status, we
- realized that the subset of patients with aneuploidy and p53 positivity had the
- worst prognosis.
- Conclusions. p53 expression and ploidy DNA estimations are useful methods
- in prognosis for bladder cancer patients. Aneuploidy and p53 expression may
- indicate high risk ofthe recurrence and progression.
references
- [1] Casetta, G., Gontero, R, Russo, R., Tizzani, A.: p53 ekspression compared
- with other prognostic factors in OMS grade-I, stage Tg transitional cell carcinoma of
- the bladder. Eur. Urol. 1997,32,229-236.
- [2] Dowell, S. R, Wilson, R O., Derias, N. W., et al.: Clinical utylity ofthe
- immunocytochemical detection ofthe p53 protein in cytological specimens. Cancer
- Res. 1994, 54, 2914-2918.
- [3] Glick, S. H., Howell, L. R, Devere-White, R. W.: Relationship ofp53 and
- bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J.
- Urol. 1996,155,1754-1757.
- [4] Herr, H. H., Bajorin, D. D., Scher, H. I., Cordon-Cardo, C, Reuter, V.:
- Can p53 help select patients with invasive bladder cancer for bladder preseruation?
- J. Urol., 1999,161, 20-23.
- [5] Jahnson, S., Risberg, B., Kerlsson, M. G.: p53 and Rb immunostaining in
- locally advanced bladder cancer. Eur. Urol. 1995, 28,135-142.
- [6] Kołodziej, A., Du¶, D., Lorenz, J.: Ploidia DNA a czas przeżycia pacjentów z
- guzami pęcherza moczowego; badania retrospektywne. Urol. Pol. 1997,1,19.
- [7] Kołodziej,.. A., Du¶, D., Lorenz, J.: Warto¶ć prognostyczna ploidii DNA w
- rakach pęcherza moczowego. Urol. Pol. 1996,4,12.
- [8] Lipponen, P. K.: Over-expression ofp53 nuclear oncoprotein in transitional cell
- bladder cancer and its prognostic value. Int. J. Cancer 1993, 53,1393-1398.
- [9] Lowe, S., Ruley, H.: p53 dependent apopoptosis modulates the cytotoxidty of
- anticancer agents. Cell 1993, 74, 957-967.
- [10] Moch, H., Sauter, G., Mitatsh, M. J. et al.: p53 but not erbB-2 expression is
- associated with rapid tumour proliferation in urinary bladder cancer. Hum. Pa-
- thol. 1994, 25,1346-1351.
- [11] Morkve, O., Laerum, O. D.: Flow cytometric measurement of p53 expression
- and DNA content in bronchial carcinomas. Cytometry 1981,12, 438-444.
- [12] Ovesen, H., Horn, T., Steven, K.: Long-term efficacy of intravesical BCG for
- carcinoma in situ; relationship of progression to histopathological responce and p53
- accumulation. J. Urol. 1997,157,1655-1659.
- [13] Ozdemir, E., Kakehi, Y., Okuno, H., Yoshida, O.: Strong correlation of
- basement membrane degradation with p53 inactwation and/or MDM2 overexpres-
- sion in superficial urothelial carcinomas. J. Urol. 1997,158, 206-211.
- [14] Pfister, Ch., Buzelin, F., Casse, Ch. et al.: Comparative analysis of MiBl
- and p53 expression in human bladder tumors and their correlation with progression.
- Eur. Urol. 1998, 33, 278-284.
- [15] Raitanen, M. R, Tammela, T. L., Kallioinen, M., Isola, J.:p53 accumula-
- tion, DNA ploidy and progression of bladder cancer. J. Urol. 1997,157,1250-1253.
- [16] Scott, N., Sagar, P., Steward, J. et al.: p53 in colorectal cancer. Br. J. Cancer
- 1991, 61, 369.
- [17] Sherman, C. D.: Onkologia kliniczna. PZWL, Warszawa 1992.
- [18] Skinner, D. G., Lieskovski, G.: Management of invasive and high grade blad-
- der cancer. In: Diagnosis and management of genitourinary cancer. D. G. Skinner
- and D. G., Lieskovski (eds.),.Philadelphia 1996. W. B. Saunders Co., 295-312.
- [19] U. I. CC: TNM classification of malignant tumours. Geneva 1998.
- [20] Ye, D., Zheng, J., Qian, S., Ma, Y.: Expression of p53 product in chinese hu-
- man bladder human carcinoma. Urol. Res. 1993, 21, 223-226.
- [21] Zatoński, W.: Nowotwory zło¶liwe w Polsce w 1989 roku. ZOWzRiEN, War-
- szawa 1992.
|